Agios Pharmaceuticals, a pre-clinical stage biotech developing small molecule treatments for cancer and inborn errors of metabolism, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2007 and booked $25 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol AGIO. Agios Pharmaceuticals initially filed confidentially on May 23, 2013. J.P. Morgan and Goldman Sachs are the joint bookrunners on the deal. No pricing terms were disclosed.
